3-(5-bromo-1,4-dioxopentyl)-4(S)-(1-methylethyl)-2-oxazolidinone | 160447-17-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-(5-bromo-1,4-dioxopentyl)-4(S)-(1-methylethyl)-2-oxazolidinone
• 英文别名: 5-bromo-1-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pentane-1,4-dione
• CAS: 160447-17-6
• 化学式: C₁₁H₁₆BrNO₄
• 分子量: 306.156
• InChiKey: FRKBIFIASRZPOK-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  63.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(5-bromo-1,4-dioxopentyl)-4(S)-(1-methylethyl)-2-oxazolidinone 在 4-二甲氨基吡啶 、 sodium hexamethyldisilazane 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 、 硫脲 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 48.5h， 生成 {4-[(R)-2-{[Dimethylcarbamoylmethyl-(1-hydroxy-cyclohexylmethyl)-carbamoyl]-methyl}-3-((S)-4-isopropyl-2-oxo-oxazolidin-3-yl)-3-oxo-propyl]-thiazol-2-yl}-carbamic acid 2,2,2-trichloro-ethyl ester
  参考文献：
  名称：

  Discovery of non-peptidic P 2 –P 3 butanediamide renin inhibitors with high oral efficacy

  摘要：

  A new series of non-peptidic renin inhibitors having a 2-substituted butanediamide moiety at the P-2 and P-3 positions has been identified. The optimized inhibitors have IC50 values of 0.8 to 1.4 nM and 2.5 to 7.6 nM in plasma renin assays at pH 6.0 and 7.4, respectively. When evaluated in the normotensive cynomolgus monkey model, two of the most potent inhibitors were orally active at a dose as low as 3 mg/kg. These potent renin inhibitors are characterized by oral bioavailabilities of 40 and 89% in the cynomolgus monkey. Inhibitor 3z (BILA 2157 BS) was selected as candidate for pre-development. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)00265-x
• 作为产物：
  描述：

  3-(3-carboxy-1-oxopropyl)-4(S)-(1-methylethyl)-2-oxazolidinone 在 草酰氯 、 氢溴酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.92h， 生成 3-(5-bromo-1,4-dioxopentyl)-4(S)-(1-methylethyl)-2-oxazolidinone
  参考文献：
  名称：

  Discovery of non-peptidic P 2 –P 3 butanediamide renin inhibitors with high oral efficacy

  摘要：

  A new series of non-peptidic renin inhibitors having a 2-substituted butanediamide moiety at the P-2 and P-3 positions has been identified. The optimized inhibitors have IC50 values of 0.8 to 1.4 nM and 2.5 to 7.6 nM in plasma renin assays at pH 6.0 and 7.4, respectively. When evaluated in the normotensive cynomolgus monkey model, two of the most potent inhibitors were orally active at a dose as low as 3 mg/kg. These potent renin inhibitors are characterized by oral bioavailabilities of 40 and 89% in the cynomolgus monkey. Inhibitor 3z (BILA 2157 BS) was selected as candidate for pre-development. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)00265-x

文献信息

• N-(Hydroxyethyl)butanediamide derivatives as renin inhibitors
  申请人：BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC.

  公开号：EP0589446A1

  公开（公告）日：1994-03-30

  Disclosed herein are compounds of the formula:         A-N(R¹)C(O)CH₂CHR²C(O)-B wherein A is an oxygen-bearing radical selected from the group consisting of: (a) HO-CH(R³)CH₂ wherein R³ is, for example, hydrogen, lower alkyl, lower cycloalkyl, phenyl or an unsubstituted five- or six-membered heterocyclic ring containing one or two heteroatoms selected from the group of N, O or S; (b) HO-CH₂CH(R⁴) wherein R⁴ is, for example, lower alkyl or phenyl(lower)alkyl; and (c) HO-CR⁵(R⁶)CH₂ wherein each of R⁵ and R⁶ is lower alkyl; or R⁵ and R⁶ together with the carbon atom to which they are attached form a 1,1-(lower cycloalkanediyl), 1,1-(4-hydroxycyclohexanediyl) or 1,1-(4-oxocyclohexanediyl); (d) (lower alkoxy)CR5A(R6A)CH₂ wherein each of R5A and R6A is lower alkyl; or R5A and R6A together with the carbon atom to which they are attached form a 1,1-(lower cycloalkanediyl); and (e) (lower alkyl)C(O)CH₂; R¹ is, for example, benzyl, alkyl, a substituted alkyl such as cyclohexylmethyl, or R⁷R⁸NC(O)CH₂ wherein R⁷ and R⁸ are alkyl such as methyl or ethyl; R² is, for example, alkyl, cycloalkylmethyl, 1H-imidazol-4-ylmethyl, 4-thiazolylmethyl or (2-amino-4-thiazolyl)methyl; and B is a renin substrate transition state mimic, for example, [1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]amino. The compounds inhibit renin activity and are indicated for the treatment of hypertension and congestive heart failure.

  这里公开的是式中的化合物： A-N(R¹)C(O)CH₂CHR²C(O)-B 其中 A 是选自以下组别的含氧自由基(a) HO-CH(R³)CH₂ 其中 R³ 例如是氢、低级烷基、低级环烷基、苯基或含有选自 N、O 或 S 组的一个或两个杂原子的未取代的五元或六元杂环； (b) HO-CH₂CH(R⁴) 其中 R⁴ 例如是低级烷基或苯基（低级）烷基；(c) HO-CR⁵(R⁶)CH₂，其中 R⁵ 和 R⁶ 均为低级烷基；或 R⁵ 和 R⁶ 与它们所连接的碳原子一起形成 1,1-(低级环烷二基)、1,1-(4-羟基环己烷二基)或 1,1-(4-氧代环己烷二基)；(d) (低级烷氧基)CR5A(R6A)CH₂，其中 R5A 和 R6A 各为低级烷基；或 R5A 和 R6A 与它们所连接的碳原子一起形成 1,1-(低级环烷二基)；(e) (低级烷基)C(O)CH₂；R¹例如是苄基、烷基、取代的烷基如环己基甲基，或 R⁷R⁸NC(O)CH₂，其中 R⁷ 和 R⁸ 是烷基如甲基或乙基；R² 是例如烷基、环烷基甲基、1H-咪唑-4-基甲基、4-噻唑基甲基或（2-氨基-4-噻唑基）甲基；以及 B 是肾素底物过渡态模拟物，例如[1(S)-(环己基甲基)-2(R),3(S)-二羟基-5-甲基己基]氨基。这些化合物可抑制肾素活性，适用于治疗高血压和充血性心力衰竭。
• Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives
  申请人：BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC.

  公开号：EP0589445A1

  公开（公告）日：1994-03-30

  Disclosed herein are compounds of the formula:         A-N(R¹)C(O)CH₂CHR²C(O)-B wherein A is R³R⁴NC(O)CH₂ wherein, for example, R³ is hydrogen or alkyl and R⁴ is hydrogen, alkyl or a substituted alkyl such as 2-(2-pyridinyl)ethyl, or R³ and R⁴ together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino or thiomorpholino; R¹ is, for example, benzyl, alkyl or a substituted alkyl such as cyclohexylmethyl; R² is, for example, alkyl, cycloalkylmethyl, 1H-imidazol-4-ylmethyl, 4-thiazolylmethyl or (2-amino-4-thiazolyl)methyl; and B is a renin substrate transition state analog, for example, [1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]amino. The compounds inhibit renin activity and are indicated for the treatment of hypertension and congestive heart failure.

  这里公开的是式中的化合物： A-N(R¹)C(O)CH₂CHR²C(O)-B 其中 A 是 R³R⁴NC(O)CH₂，例如，R³是氢或烷基，R⁴是氢、烷基或取代的烷基，如 2-(2-吡啶基)乙基，或 R³ 和 R⁴ 与它们所连接的氮原子一起形成吡咯烷基、哌啶基、吗啉基或硫代吗啉基；R¹例如是苄基、烷基或取代的烷基，如环己基甲基；R²例如是烷基、环烷基甲基、1H-咪唑-4-基甲基、4-噻唑基甲基或（2-氨基-4-噻唑基）甲基；B是肾素底物过渡态类似物，例如[1(S)-(环己基甲基)-2(R),3(S)-二羟基-5-甲基己基]氨基。这些化合物可抑制肾素活性，适用于治疗高血压和充血性心力衰竭。
• US5523315A
  申请人：——

  公开号：US5523315A

  公开（公告）日：1996-06-04
• US5541163A
  申请人：——

  公开号：US5541163A

  公开（公告）日：1996-07-30
• US5554634A
  申请人：——

  公开号：US5554634A

  公开（公告）日：1996-09-10